bpc-157 human clinical trial 2024 randomized controlled Wolverine Stack: Healing Faster with Peptides BPC-157 & TB-500: What You
Description
The STEP clinical trial program reported that approximately 74% of participants on semaglutide 2.4mg experienced at least one gastrointestinal adverse event
Angiogenesis and Blood Supply Limited blood supply represents one of the biggest obstacles to tendon healing
(insider note - the scientist was blown away reading the results from peptides) In this issue: What peptides actually are The ones worth knowing: GLP-1, BPC-157, GHK-Cu, Retatrutide and others A 100-year-old unsolved problem: why oral delivery is so hard The grey market flooding in from China and what HSA and FDA are saying The Hims & Hers episode: what happened when the company skipped the science Where we are at Xandro with BPC-157 1
The two peptides engage entirely different biological mechanisms
Are B12 Injections Better Than Supplements
